Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents.

Microsomal prostaglandin E(2) synthase (mPGES)-1 catalyzes the transformation of PGH(2) to PGE(2) that is involved in several pathologies like fever, pain, and inflammatory disorders. To identify novel mPGES-1 inhibitors, we used in silico screening to rapidly direct the synthesis, based on the copper-catalyzed 3 + 2 Huisgen's reaction (click chemistry), of potential inhibitors. We designed 26 new triazole-based compounds in accordance with the pocket binding requirements of human mPGES-1. Docking results, in agreement with ligand efficiency values, suggested the synthesis of 15 compounds that at least in theory were shown to be more efficient in inhibiting mPGES-1. Biological evaluation of these selected compounds has disclosed three new potential anti-inflammatory drugs: (I) compound 4 displaying selectivity for mPGES-1 with an IC(50) value of 3.2 μM, (II) compound 20 that dually inhibits 5-lipoxygenase and mPGES-1, and (III) compound 7 apparently acting as 5-lipoxygenase-activating protein inhibitor (IC(50) = 0.4 μM).

[1]  R. Riccio,et al.  Development of a second generation of inhibitors of microsomal prostaglandin E synthase 1 expression bearing the gamma-hydroxybutenolide scaffold. , 2008, Bioorganic & medicinal chemistry.

[2]  O. Werz 5-lipoxygenase: cellular biology and molecular pharmacology. , 2002, Current drug targets. Inflammation and allergy.

[3]  Sunil Badve,et al.  Microsomal prostaglandin E2 synthase‐1 in breast cancer: a potential target for therapy , 2006, The Journal of pathology.

[4]  O. Werz,et al.  Inhibitors of the microsomal prostaglandin E(2) synthase-1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs)--a critical review. , 2009, Current medicinal chemistry.

[5]  G. Schneider,et al.  Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. , 2010, Journal of medicinal chemistry.

[6]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[7]  Jilly F. Evans,et al.  Crystal Structure of Inhibitor-Bound Human 5-Lipoxygenase-Activating Protein , 2007, Science.

[8]  J. Salmon,et al.  Selective inhibition of arachidonate 5‐lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo , 1988, British journal of pharmacology.

[9]  Chang-Guo Zhan,et al.  Understanding microscopic binding of human microsomal prostaglandin E synthase-1 with substrates and inhibitors by molecular modeling and dynamics simulation. , 2008, The journal of physical chemistry. B.

[10]  Alfonso T. García-Sosa,et al.  Structure-based calculation of drug efficiency indices , 2007, Bioinform..

[11]  H. Kolb,et al.  The growing impact of click chemistry on drug discovery. , 2003, Drug discovery today.

[12]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[13]  P. Paty,et al.  Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  B. Samuelsson,et al.  Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Lihe Zhang,et al.  A Convenient Preparation of 5‐Iodo‐1,4‐disubstituted‐1,2,3‐triazole: Multicomponent One‐Pot Reaction of Azide and Alkyne Mediated by CuI—NBS. , 2008 .

[16]  Robert Fletterick,et al.  The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity , 1997, Nature Structural Biology.

[17]  Xiaohua Jiang,et al.  A fragment-based in situ combinatorial approach to identify high-affinity ligands for unknown binding sites. , 2010, Angewandte Chemie.

[18]  R. DuBois,et al.  PROSTAGLANDINS AND CANCER , 2005, Gut.

[19]  N. Méthot,et al.  Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. , 2005, Bioorganic & medicinal chemistry letters.

[20]  Calvin Yu-Chian Chen,et al.  Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping , 2009 .

[21]  V. Fokin,et al.  Copper-catalyzed reaction cascade: direct conversion of alkynes into N-sulfonylazetidin-2-imines. , 2006, Angewandte Chemie.

[22]  S. Cho,et al.  3D-QSAR study of microsomal prostaglandin E2 synthase(mPGES-1) inhibitors , 2007 .

[23]  P. McGettigan,et al.  Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.

[24]  Wolfgang Albrecht,et al.  Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[25]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[26]  Chang-Guo Zhan,et al.  Human Microsomal Prostaglandin E Synthase-1 (mPGES-1) Binding with Inhibitors and the Quantitative Structure-Activity Correlation , 2008, J. Chem. Inf. Model..

[27]  Luke G Green,et al.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. , 2002, Angewandte Chemie.

[28]  G. Burmester,et al.  Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. , 2001, The American journal of medicine.

[29]  Ralf Morgenstern,et al.  Structural basis for detoxification and oxidative stress protection in membranes. , 2006, Journal of molecular biology.

[30]  J. Mancini,et al.  Microsomal Prostaglandin E2 Synthase‐1 (mPGES‐1): A Novel Antiinflammatory Therapeutic Target , 2008 .

[31]  QM and Pharmacophore based 3D-QSAR of MK886 Analogues against mPGES-1 , 2008 .

[32]  J. Gierse,et al.  Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template. , 2010, Bioorganic & medicinal chemistry letters.

[33]  Hans Peter Nestler Combinatorial chemistry and fragment screening--two unlike siblings? , 2005, Current drug discovery technologies.

[34]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[35]  J. Moses,et al.  The Growing Applications of Click Chemistry , 2007 .

[36]  K. Sharpless,et al.  Copper‐Catalyzed Synthesis of N‐Sulfonyl‐1,2,3‐triazoles: Controlling Selectivity. , 2007 .

[37]  M. G. Finn,et al.  In situ Click Chemistry: Probing the Binding Landscapes of Biological Molecules , 2010 .

[38]  N. Méthot,et al.  Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[39]  Ralf Morgenstern,et al.  Human Microsomal Prostaglandin E Synthase-1 , 2003, Journal of Biological Chemistry.

[40]  Yves Bureau,et al.  Microsomal Prostaglandin E Synthase-1 Is a Major Terminal Synthase That Is Selectively Up-Regulated During Cyclooxygenase-2-Dependent Prostaglandin E2 Production in the Rat Adjuvant-Induced Arthritis Model , 2003, The Journal of Immunology.

[41]  G. Schneider,et al.  The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5‐lipoxygenase products , 2007, British journal of pharmacology.

[42]  Makoto Murakami,et al.  Regulation of Prostaglandin E2 Biosynthesis by Inducible Membrane-associated Prostaglandin E2 Synthase That Acts in Concert with Cyclooxygenase-2* , 2000, The Journal of Biological Chemistry.

[43]  Fan Zhang,et al.  Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  M. Jett,et al.  Effect of 5‐lipoxygenase inhibitor MK591 on early molecular and signaling events induced by staphylococcal enterotoxin B in human peripheral blood mononuclear cells , 2008, The FEBS journal.

[45]  W. Dehaen,et al.  A microwave-assisted click chemistry synthesis of 1,4-disubstituted 1,2,3-triazoles via a copper(I)-catalyzed three-component reaction. , 2004, Organic letters.

[46]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[47]  A. Hamza,et al.  Understanding microscopic binding of human microsomal prostaglandin E synthase-1 (mPGES-1) trimer with substrate PGH2 and cofactor GSH: insights from computational alanine scanning and site-directed mutagenesis. , 2010, The journal of physical chemistry. B.

[48]  V. Fokin,et al.  Practical Synthesis of Amides from in situ Generated Copper(I) Acetylides and Sulfonyl Azides. , 2006 .

[49]  Substituted Phenanthrene Imidazoles as Potent, Selective, and Orally Active mPGES-1 Inhibitors. , 2008 .

[50]  Johan Wouters,et al.  Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target-based approach. , 2006, Journal of medicinal chemistry.

[51]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[52]  Ralf Morgenstern,et al.  Structural basis for induced formation of the inflammatory mediator prostaglandin E2 , 2008, Proceedings of the National Academy of Sciences.